These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22958146)

  • 1. Gastrointestinal disorders and dabigatran.
    Hoffman A; Galle PR
    Scand J Gastroenterol; 2013 Jan; 48(1):9-16. PubMed ID: 22958146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
    Bovio JA; Smith SM; Gums JG
    Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran in clinical practice.
    Nagarakanti R; Ellis CR
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.
    Tran A; Cheng-Lai A
    Cardiol Rev; 2011; 19(3):154-61. PubMed ID: 21464643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
    Iyer V; Singh HS; Reiffel JA
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):237-47. PubMed ID: 22388002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML; Blommel AL
    Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dabigatran as an alternative to warfarin for the prevention of thromboembolism in atrial fibrillation].
    De Caterina R; Renda G
    G Ital Cardiol (Rome); 2012 Nov; 13(11 Suppl 1):19S-27S. PubMed ID: 23160016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.